New PET-MRI tracer could sharpen prostate cancer biopsy accuracy

NCT ID NCT06865768

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial tests whether combining a radioactive tracer (18F-rhPSMA-7.3) with PET and multiparametric MRI can better identify clinically significant prostate cancer than MRI alone. Men suspected of having prostate cancer will receive the tracer and undergo imaging before a targeted biopsy. The goal is to see if the tracer's activity in suspicious areas improves the detection of aggressive tumors, potentially making biopsies more accurate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 18F-rhPSMA-7.3 (flotufolastat F-18) given intravenously, plus magnetic resonance imaging (MRI)
What this could lead to
If successful, this imaging method could help doctors more accurately identify aggressive prostate cancers during biopsy, reducing unnecessary procedures and improving treatment decisions.
What could go wrong
This is a phase II trial with only 90 participants, so results may not apply to all men. The technique may not significantly outperform standard MRI, and there are small risks from radiation exposure and MRI contraindications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.